Drugs / LD-AraC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02351037 | Feb 2015 → Apr 2017 | acute myeloid leukemia | Pharmacyclics LLC. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LD-AraC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02351037 ↗ |
| Route | Subcutaneous | “cytarabine dose (20 mg BID sc)” NCT02351037 ↗ |